Management and outcome of locally advanced oral squamous cell carcinoma.

Autor:	Bera RN; Department of Oral and Maxillofacial Surgery, Dental Institute Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India., Tandon S; Department of Oral and Maxillofacial Surgery, Career Post Graduate Institute of Dental Sciences and Hospital, Lucknow, Uttar Pradesh, India., Singh AK; Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences Institute of Medical Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India., Boojar FMA; Golestan University of Medical Sciences, Gorgan, Iran., Jaiswal G; Department of Oral and Maxillofacial Surgery, Career Post Graduate Institute of Dental Sciences and Hospital, Lucknow, Uttar Pradesh, India., Borse S; Department of Oral and Maxillofacial Surgery, Career Post Graduate Institute of Dental Sciences and Hospital, Lucknow, Uttar Pradesh, India., Pal US; Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences Kings George Medical University, Lucknow, Uttar Pradesh, India., Sharma NK; Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences Institute of Medical Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Jazyk:	angličtina
Zdroj:	National journal of maxillofacial surgery [Natl J Maxillofac Surg] 2023 May-Aug; Vol. 14 (2), pp. 185-189. Date of Electronic Publication: 2023 Jul 13.
DOI:	10.4103/njms.njms_125_22
Abstrakt:	Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease. Competing Interests: There are no conflicts of interest. (Copyright: © 2023 National Journal of Maxillofacial Surgery.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu